Additionally, we observed a higher rate of lymph node metastasis in the HER2-ultralow group, as well as a larger tumor size compared to both the HER2-null and HER2-low groups. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.